The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Retrospective study for the characterization of COVID-19 in renal cancer (COVID-REN) patients treated with antiangiogenics or immunotherapy and outcome comparison with non-infected cases.
 
Jesus Garcia Donas
Research Funding - Astellas Amgen BioPharama; AstraZeneca; BMS Brazil; GamaMabs Pharma; Pfizer; Pierre Fabre; Rainier Therapeutics; Roche; Takeda
Other Relationship - Amgen; Astellas Amgen BioPharama; AstraZeneca; BMS Brazil; Clovis Oncology; Ipsen; Janssen; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Tesaro
 
Guillermo de Velasco
Honoraria - Ipsen; Pfizer
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; MSD; MSD; Novartis; Pfizer
Research Funding - Ipsen
Other Relationship - Janssen
 
Teresa Alonso Gordoa
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Merck; Pfizer; Roche; Sanofi
Research Funding - Ipsen; Pfizer; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Pfizer; Sanofi
 
Jesús Chamorro
No Relationships to Disclose
 
Diana Rosero
No Relationships to Disclose
 
Olatz Etxaniz
No Relationships to Disclose
 
Jose Luis Perez-Gracia
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Pierre Fabre; Roche; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Eisai; MSD; Roche
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Incyte (Inst); Janssen (Inst); MSD (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche
 
Alvaro Pinto
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi/Aventis
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; Pfizer; Roche
 
Ignacio Duran
Honoraria - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen Oncology; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Immunomedics; Janssen Oncology; MSD Oncology; Novartis; Pharmacyclics; Roche/Genentech; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca Spain (Inst); Janssen Oncology (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Ipsen; Roche/Genentech
 
Diego Cacho
No Relationships to Disclose
 
María Barba
No Relationships to Disclose
 
Monica Yagüe
No Relationships to Disclose
 
Pablo Borrega
No Relationships to Disclose
 
Martín Lázaro
No Relationships to Disclose
 
Laura Rodriguez
No Relationships to Disclose
 
Maria Laura L. Villalobos Leon
No Relationships to Disclose
 
Xavier Garcia del Muro
No Relationships to Disclose
 
Lourdes Garcia Sanchez
No Relationships to Disclose
 
M. Andres Cuellar
No Relationships to Disclose
 
Juan Francisco Rodriguez-Moreno
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Novartis
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche